While Dr Reddy#39;s recorded its highest-ever quarterly revenue in Q3, most of the growth was fueled by a higher-than-expected contribution from cancer drug Revlimid while the base US and India business delivered a subpar performance.
While Dr Reddy#39;s recorded its highest-ever quarterly revenue in Q3, most of the growth was fueled by a higher-than-expected contribution from cancer drug Revlimid while the base US and India business delivered a subpar performance. While Dr Reddy#39;s recorded its highest-ever quarterly revenue in Q3, most of the growth was fueled by a higher-than-expected contribution from cancer drug Revlimid while the base US and India business delivered a subpar performance. Moneycontrol Latest News Read More
English 
हिन्दी